Siderophore Biosynthesis Inhibitors: A Novel Strategy Against Microbial Virulence and Resistance Original paper

Researched by:

  • Karen Pendergrass ID
    Karen Pendergrass

    User avatarKaren Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease—four years before the first published case study.

    Read More

August 22, 2025

  • Metals
    Metals

    Heavy metals influence microbial pathogenicity in two ways: they can be toxic to microbes by disrupting cellular functions and inducing oxidative stress, and they can be exploited by pathogens to enhance survival, resist treatment, and evade immunity. Understanding metal–microbe interactions supports better antimicrobial and public health strategies.

  • Microbes
    Microbes

    Microbes are microscopic organisms living in and on the human body, shaping health through digestion, vitamin production, and immune protection. When microbial balance is disrupted, disease can occur. This guide explains key microbe types—bacteria, viruses, fungi, protozoa, and archaea—plus major pathogenic and beneficial examples.

Researched by:

  • Karen Pendergrass ID
    Karen Pendergrass

    User avatarKaren Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease—four years before the first published case study.

    Read More

Last Updated: 2025-08-22

Microbiome Signatures identifies and validates condition-specific microbiome shifts and interventions to accelerate clinical translation. Our multidisciplinary team supports clinicians, researchers, and innovators in turning microbiome science into actionable medicine.

Karen Pendergrass

Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease—four years before the first published case study.

What was reviewed?

This comprehensive review explores the inhibition of siderophore biosynthesis as a promising antimicrobial strategy, particularly in the context of increasing resistance to conventional antibiotics. Siderophores—small, high-affinity iron-chelating compounds secreted by microbes—are essential for pathogenic survival under iron-limited conditions. The review delineates three main siderophore biosynthetic pathways: nonribosomal peptide synthetase (NRPS)-dependent, polyketide synthase (PKS)-based, and NRPS-independent (NIS) systems. It presents siderophore production as a key virulence factor and offers an extensive analysis of enzyme targets, including NRPS adenylation domains, phosphopantetheinyl transferases (PPTases), salicylate synthases, and siderophore transport systems. Recent advances in rational drug design, nanoparticle delivery systems, and CRISPR-based genetic manipulation are also explored as innovative tools to suppress microbial iron acquisition. This review consolidates a fragmented literature base, presenting a unified therapeutic framework for antimicrobial intervention by targeting microbial iron uptake pathways.

Who was reviewed?

The review synthesizes data from a broad range of microbial taxa, including bacteria such as Mycobacterium tuberculosis, Staphylococcus aureus, Pseudomonas aeruginosa, Bacillus anthracis, and fungi such as Aspergillus fumigatus. These organisms span both Gram-negative and Gram-positive pathogens and include non-tuberculous mycobacteria (NTMs). Emphasis is placed on their shared reliance on siderophore systems for iron acquisition and pathogenesis. The microbial targets are selected based on their clinical relevance in antimicrobial resistance, virulence, and capacity to biosynthesize diverse siderophore classes.

Most important findings

The review identifies and characterizes a wide array of inhibitors and intervention strategies that target siderophore biosynthesis, grouped by enzyme class and mechanism of action. The review also highlights: Use of CRISPR-Cas9 to disrupt siderophore biosynthetic genes. Nanoparticles (e.g., zinc oxide, gold) as delivery tools and direct inhibitors of siderophore-mediated virulence. The distinction between bactericidal and antivirulence approaches, where the latter may reduce selective resistance pressures. Below is a condensed summary in table format:

Enzyme TargetInhibitor ClassExample Compound(s)IC₅₀ RangeTarget Organism(s)
PPTase (NRPS)Allosteric InhibitorsML2670.29 µMS. aureus, B. subtilis
PPTase (PptT in M. tb)Amidino-urea analoguesCompounds 1–100.018–8.29 µMM. tuberculosis
Adenylation domains (NRPS)Salicyl-AMS & derivativesSalicyl-AMS, Compound 1510.7–12 nMM. tuberculosis, Y. pestis
Salicylate Synthase (MbtI)Furanic inhibitorsCompounds 19–222.6–12.1 µMM. tuberculosis, M. abscessus
DHB Adenylation DomainsBisubstrate analogsDHB-AMS, Compound 234.5–85 nME. coli, B. subtilis
NIS SynthetaseNatural productsBaulamycin A & B4.8–200 µMS. aureus, B. anthracis
SidA (fungal hydroxylase)Natural product (noncompetitive)Celastrol11 µMA. fumigatus
FAAL/FACL (PKS-like enzymes)Fatty acyl-AMS analoguesHexanoyl-AMS, etc.NAM. tuberculosis

Key implications

Targeting siderophore biosynthesis presents a viable strategy for next-generation antimicrobial therapies, especially against multidrug-resistant organisms. Inhibitors that act on PPTases, adenylation domains, and salicylate synthases can impair iron acquisition and attenuate virulence without necessarily killing the pathogen, potentially reducing evolutionary pressures for resistance. The specificity of some inhibitors, such as ML267 and Salicyl-AMS analogues, enables narrow-spectrum approaches, while nanoparticle systems offer targeted delivery and immune synergy. The integration of genetic tools such as CRISPR enables mechanistic dissection of iron acquisition and opens avenues for strain engineering in microbial therapeutics. However, challenges remain in achieving selectivity, in vivo stability, and delivery to biofilm-embedded pathogens. Further exploration of NIS and fungal-specific pathways is warranted to diversify the antimicrobial toolkit.

Citation

Rocha BM, Pinto E, Sousa E, Resende DISP. Targeting siderophore biosynthesis to thwart microbial growth. Int J Mol Sci. 2025;26(8):3611. doi:10.3390/ijms26083611

Siderophores

Siderophores are microbial iron-chelating molecules that enable pathogens to overcome host iron restriction, shape microbiome ecology, and serve as therapeutic targets.

Siderophores

Siderophores are microbial iron-chelating molecules that enable pathogens to overcome host iron restriction, shape microbiome ecology, and serve as therapeutic targets.

Staphylococcus aureus (S. Aureus)

Staphylococcus aureus is a versatile skin and mucosal commensal that can transition into a highly virulent pathobiont. Known for its immune-evasive strategies, toxin production, and antibiotic resistance, it plays a significant role in chronic infections and microbiome imbalance.

Gram-Negative Bacteria

Gram-negative bacteria are resilient pathogens with antibiotic resistance, causing infections like UTIs, sepsis, and pneumonia.

Siderophores

Siderophores are microbial iron-chelating molecules that enable pathogens to overcome host iron restriction, shape microbiome ecology, and serve as therapeutic targets.

Join the Roundtable

Contribute to published consensus reports, connect with top clinicians and researchers, and receive exclusive invitations to roundtable conferences.